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and 3Cabinet Mkdical, Batiment A2, Marseille, France 
Objective: To evaluate the advantage of antibiotic therapy in the treatment of acute bronchitis in terms of efficacy, 
safety and quality of life in otherwise healthy adults under 65 years of age. 
Methods: This multicenter double-blind trial was carried out in the community on two parallel groups, antibiotic versus 
placebo. 
Results: Cure rates at the end of the treatment (8 days) were similar in the two groups (81.9% in  the treatment group 
and 84.6% in the placebo group). On the other hand, the number of patients who developed a secondary focal infection 
was lower in the treatment group than in  the placebo group at the end of treatment (1.1% and 6.5% respectively, 
p= 0.06) and after 28 days of follow-up (5.3% and 12.0% respectively, p=0.05). Health-related quality of life assessed by 
the SF-36 questionnaire showed that patients in  the treatment group declared more beneficial changes after 8 days than 
patients in the placebo group, with mean scores of 78.1 and 70.5 respectively (p=0.03). 
Conclusion: Antibiotic therapy of acute bronchitis did not influence the clinical cure rate or outcome of symptoms. 
However, the results suggest that it reduced the risk of secondary focal bacterial infections and may have improved the 
patient's quality of life in some respects. 
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INTRODUCTION 
Acute bronchitis is an acute inflammation of the 
bronchi and/or bronchioles, leading to cough with 
purulent or mucopurulent sputum [l-31. It  is a very 
frequent condition, being one of the 10 most frequent 
diagnoses in community practice. The initial etiology 
is usually viral [4,5], meaning that antibiotic therapy is 
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not always warranted [1,61. However, antibiotics should 
be prescribed, according to French guidelines, to 
patients with bronchial rales and persistent cough and 
purulent expectoration, or risk factors such as smoking, 
advanced age or a history of chronic bronchitis [1,6]. 
Bacterial colonization and superinfection are common 
[4] and so the prescribed antibiotic must be capable of 
treating or preventing this possibility [2,7], 
The efficacy of antibiotic therapy has been demon- 
strated in patients with exacerbations of chronic 
bronchitis [8-101. Anthonisen et a1 [8] showed that 
antibiotic therapy was more effective than a placebo 
when patients had at least three of the following 
symptoms: increased dyspnea, increase in  sputum 
volume, and purulent sputum. When two of the three 
symptoms were present at  onset, antibiotic therapy 
could probably be justified, according to the author. 
Otherwise, placebo-controlled trials involving healthy 
adults with acute bronchitis have given conflicting 
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results. Among six trials [2,7,11-141, two [7,11] sug- 
gested that antibiotic therapy was efficacious in this 
setting. In one study [2], a benefit was described among 
patients more than 55 years old. We therefore conducted 
a placebo-controlled trial to determine the efficacy of 
an antibiotic regimen devised for the treatment of acute 
bronchitis in otherwise healthy adults under 65 years of 
age. Efficacy was assessed in terms of both clinical and 
quality-of-life criteria. 
METHODOLOGY 
The trial was conducted between January and May 
1992. It was a multicenter, double-blind, randomized 
study with two parallel groups. The protocol had been 
approved by the ethics committee of Toulouse (France), 
and the patients provided written informed consent. 
Patients 
The study population consisted of adults under 65 years 
of age with acute bronchitis defined by the onset, less 
than 7 days previously, of cough and purulent or 
mucopurulent sputum, and able to fill in a quality-of- 
life questionnaire and an individual symptom diary. 
Patients with focal crackles or chronic bronchitis (cough 
and excessive sputum production for periods of at least 
3 months in each of the previous 2 years) or clinical 
signs of another site of infection requiring antibiotic 
therapy were ineligible. Other exclusion criteria were 
chronic liver and kidney disease, gastroduodenal ulcer 
(patients unable to receive carbocysteine), allergy to 
cephalosporins, systemic antibiotics less than 8 days 
prior to enrollment, pregnancy and breast-feeding. 
Asthma was not an exclusion criterion. 
Treatment 
The study drug was cefuroxime axetil, 250 mg twice 
a day. The subjects were randomly assigned to the 
placebo group or the treatment group. Treatment 
lasted 8 days in each group, with twice-daily dosing 
(one tablet morning and evening, after meals). The 
compliance was assessed by checking returned blister 
packs and unused study medication. All the patients 
received carbocysteine as symptomatic treatment. Other 
symptomatic treatments (NSAIDs, antitussives, etc.) 
were permitted. Long-term treatments for chronic 
conditions and those necessitated by non-infectious 
intercurrent events were also allowed. Other systemic 
antibiotics and steroids were not permitted. 
Study procedures 
Each subject was assessed four times during the 28-day 
study period: at enrollment, during treatment (D2), 
at  the end of treatment (D8-Dl0) and post-treatment 
(D28). The first three assessments (DO, D2 and 
D8-Dl0) comprised an interview and a physical 
examination. A chest radiograph was obtained less than 
48 h after the onset of treatment and interpreted at the 
D2 visit. When pneumonia was diagnosed at this stage, 
the code was broken, the patient was withdrawn and 
appropriate antibiotic treatment was started. The post- 
treatment assessment (D28) consisted of a telephone 
interview and, according to the state of the patient, a 
physical examination. So, if after the phone interview 
the investigator thought that the patient might have a 
focal bacterial infection, the patient came back to the 
GP office for a physical examination. At enrollment, 
each patient was given a personal diary in which 
to record symptoms daily (general condition, fever, 
expectoration, cough and fatigue). 
Clinical and quality-of-life assessment 
The main endpoint was clinical eRicacy on D8. What 
was important was the purulent character of sputum: 
colored sputum exclusively or white (mucous) and 
purulent (yellow, green) sputum. This assessment was 
explained to the patient. Cure was defined as the 
disappearance of purulent sputum and the absence of a 
focal bacterial infection; failure was defined as the 
persistence of purulent sputum cir the diagnosis of a 
local bacterial infection requiring further antibiotic 
therapy. Secondary clinical endpoints were fever, 
sputum production, cough, fatigue, general condition, 
the time required for symptoms to resolve, the onset of 
a new focus of infection, the tolerability of the treat- 
ment and the investigators’ overall judgment. Health- 
related quality of life (HRQoL) was also assessed by 
using the validated French version of the MOS-SF36 
questionnaire [15,16]. The quest.ionnaire was slightly 
adapted to acute diseases: patients were additionally 
asked to indicate their health status during the past 
8 days. 
Statistical analysis 
Qualitative variables were compared between the two 
groups by using the chi-squared test or Fisher’s exact 
test when the expected number of subjects in any cell 
was less than five. Quantitative variables were compared 
by using Student’s t-test or Wilcoxon’s non-parametric 
test when variables were not normally distributed. SF- 
36 data were recoded as described by the authors [15]. 
AU tests were one-sided (superiority of the treatment 
over the placebo) with a and p risks set at 5%. The 
number of subjects required to :;how at least a 20% 
difference between the two arms was 90 (per group). 
The analysis was done on an intention-to-treat basis, 
and included all patients for whom the post-treatment 
assessment was available. 
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One hundred and ninety patients were enrolled between 
January and May 1992, by 34 general practitioners. 
Three patients were excluded on D2 (two for pneu- 
monia and one lost to follow-up). One subject failed 
to complete the quality-of-life questionnaire. The 
analysis of clinical efficacy therefore included 187 
patients, 95 in the treatment group and 92 in the 
placebo group; the quality-of-life analysis included 
186 patients, 94 in the treatment group and 92 in the 
placebo group. 
Characteristics of the patients at enrollment are 
shown in Tables 1 and 2. The two treatment groups 
were similar in terms of demographic characteristics, 
smoking, asthma, baseline manifestations and quality of 
life. 
Clinical response 
As shown in Table 3, the cure rate at the end of 
treatment was not significantly different between the 
two groups (81.9% in the treatment group, 84.6% in 
the placebo group). There was no significant differ- 
ence between the two groups as regards the dis- 
appearance or time required for the disappearance of 
the other clinical manifestations (fever, cough and 
purulent sputum). In contrast, the number of patients 
who developed a focal infection on D8 was lower in 
the treatment group than in the placebo group (one 
and six respectively, ~ ~ 0 . 0 6 ) .  
This was confirmed in the end post-treatment 
assessment (D28): while the rate of relapse and recur- 
rence of purulent sputum after the end of treatment was 
not significantly different between the two groups 
(10.6% and 8.7% respectively), the number of focal 
bacterial infections was lower in the treatment group 
than in the placebo group (five and 11 respectively, 
pO.05) .  
Quality of life 
When comparing their health status on D8 to that on 
DO, patients in the treatment group declared more 
beneficial changes (mean score 78.1) than patients in 
the placebo group (mean score 70.5) (p=O.O3). 
Whatever the item in the SF-36 questionnaire, 
differences between D8 and DO did not differ signi- 
ficantly between the two groups. Subjective overall 
health improved by 2.5 points in the treatment group, 
and deteriorated by 0.5 points in the placebo group 
(p=0.08) (Table 4). 
DISCUSSION 
Acute bronchitis is usually due to a viral infection 
[4,5]. However, bacterial colonization and infection are 
frequent. Indeed, the defensive inflammatory reaction 
Table 1 Characteristics of the population at inclusion (DO) 
Treatment group 
n =95 
Placebo group 
11=92 
Total 
?r=l87 
Aze (years) ,' 
Sex 
Male 
Female 
Sex ratio 
Wright (kg).' 
Smoking 
Non-smoker 
Current smoker 
Foriiier smoker 
Astliiiin 
Symptoms 
l'urulent expectoration 
Mucopurulent expectoration 
Cough preventing slrrp 
Painful cough 
Central temperature > 37.5 "C 
F'itigue (activity reduced or impossible) 
42.5k13.6 
45 (47.4%) 
SO (52.6%) 
0.9 
69.6k1.1 5 
37 (38.9'%,) 
45 (47.4%) 
6 (6.3%) 
13 (13.7%) 
40 (42.1%) 
58 (61.1%) 
.il (53.7%) 
62 (66.3%) 
66 (69.5%) 
54 (56.8%) 
44.7 -t 13.9 
44 (47.8%) 
48 (52.2%) 
0.9 
67.2212.2 
39 (42.4%) 
17 (18.5%) 
36 (39.1%) 
7 (7.6%) 
43 (46.7%) 
60 (65.2%) 
52 (56.5%) 
60 (65.2%) 
64 (69.5%) 
48 (52.2%) 
43.6 513.8 
89 (47 6%) 
98 (52.4%) 
(!.9 
68.4 f 12.Y 
76 (40.6%) 
81 (43.3%) 
30 (16.1%) 
13 (6.0%) 
83 (44.4%) 
102 (54.5%) 
118 (63.1%) 
103 (55.1%) 
130 (69.5%) 
122 (65.8%) 
"Mean 5staridard deviation. 
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that occurs in acute bronchitis leads to hypersecretion, 
edema and reduced mucociliary clearance, favoring 
bronchial obstruction and secretional stasis, all of which 
promote bacterial colonization and infection. This 
leads to a vicious circle, as bacterial colonization and 
Table 2 SF-36 score at inclusion (DO) (mean k standard 
deviation) 
Physical functioning 
Social functioning 
Role limitations-physical 
Role limitations-emotional 
Mental health index 
Vitality 
Pain index 
General health perceptions 
Health transition 
functioning 
functioning 
Treatment group 
n=94 
Placebo group 
n=92 
70.8 (f22.5) 
79 (f22.8) 
59.9 (k41.4) 
66.5 (f39) 
64.1 (f21) 
52.8 (223) 
67.8 (f25.1) 
62.9 (f22.5) 
24.2 (f22.7) 
71.8 (f21) 
75.8 (f26.7) 
58.9 (k39.9) 
63.7 (f39.3) 
62.7 (f23.7) 
53.1 (k23.3) 
75.9 (f25) 
66.7 (k21.3) 
22.2 (k20.6) 
Table 3 Clinical response at the end of treatment @8) 
Treatment group Placebo group 
n=95 n=92 
Cure rate 
(disappearance of purulent 
expectoration and no 
secondary focal bacterial 
infection) 
Failure rate 
(persistence of purulent 
sputum or discovery of focal 
bacterial infection requiring 
antibiotic therapy) 
Symptoms 
Fever 
Disappearance (<37.5 "C) 
Time to disappearancea 
Cough 
Disappearance 
Time to disappearance" 
Purulent expectoration 
Disappearance 
Time to disappearance' 
Diagnosis of focal infectionb 
Sinusitis 
Pneumonia 
Worsening of signs of lower 
respiratory tract infection 
77 (81.9%) 77 (84.6%) 
18 (18.9%) 
60 (96.8%) 
2.8f1.6 
57 (60.6%) 
5f1.6 
78 (83.0%) 
3.8 f 2  
1 (1.1%) 
1 
0 
0 
18 (19.6%) 
54 (90.0%) 
2.6 f1.6 
47 (51.1%) 
5f1.7 
82 (90.1%) 
3.7f1.8 
6 (6.5%)h 
3 
1 
2 
"Mean (days)? standard deviation. 
bp=0.05 
Table 4 Change in quahty-of-life score (SF-36) between 
D8 and DO (mean f standard deviation) 
Physical functioning 
Social functioning 
Role limitations- 
physical functioning 
emotional functioning 
Role limitations- 
Mental health index 
Vitality 
Pain index 
General perceptions 
Treatment group 
n=94 
10.9 (k 18.5) 
-9.3 (229.8) 
- 14.9 ( 2  43.6) 
-9.9 (t46.5) 
-0.1 (t 14.6) 
-7.5 (f25.9) 
-3.2 (f25.4) 
2.5 (t 9.9) 
Placebo group 
n=92 
10.6 (f 18.8) 
-4.2 (k 25.8) 
-12.6 (f46.3) 
-2.2 (f 43.8) 
2.5 (f 16.3) 
-5.7 (f 27.9) 
-6.3 (f 25.2) 
-0.5 (f12.8)" 
"p=0.08. 
Positive change indicates beneficial progression 
infection themselves exacerbate inflammation. Several 
experimental studies have established that bacteria 
adhere more avidly to virus-infected epithelial cells 
[17], which bear a larger number of epithelial adhesion 
sites [18]. These data support antibiotic treatment of 
acute bronchitis. However, placebo-controlled studies 
conducted to date (tetracycline, erythromycin and co- 
trimoxazole) in this indication have given conflicting 
results [2,7,11-141. Two [7,11] suggested that antibiotic 
therapy was beneficial in otherw:ise healthy subjects, 
while the other four showed no significant difference 
between the two treatment groups [2,12-141. These 
differences may be explained by methodological factors, 
especially in the inclusion criteria arid treatment periods. 
This is why it was important to investigate the 
efficacy of antibiotic treatment of' acute bronchitis in 
adults, in terms of clinical outcome, superinfections 
and quality of life (which is rarely studied). Our study 
was based on a strict double-blind methodology and 
involved a homogeneous population of otherwise 
healthy adults under 65 years of age. The main end- 
point was the clinical cure rate, defined as the dis- 
appearance of purulent sputum ancl the absence of focal 
bacterial infections during follow-up. 
Cefuroxime axetil is a prodrug of cefuroxime. 
Cefuroxime has been validated in the treatment of 
lower respiratory tract infections, since it is well distri- 
buted in respiratory tract tissues [19]. Its pharmaco- 
kinetic properties allow a twice-daily dosing schedule, 
it is well tolerated and it has a broad spectrum of activity 
against the most common bacterial species responsible 
for bronchial superadded infection, i.e. Streptococcus 
pneumoniae, Haernophilus infuenzae, Moraxella catarrhalis 
and Staphylococcus aureus, regardless of P-lactamase 
secretion [20-221. This antibiotic has proven effective 
in the treatment of severe lower respiratory tract 
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infections in adults, such as exacerbations of chronic 
bronchitis and pneumonia [23]. 
Like other authors [2,12-141, we found no signi- 
ficant difference between the treatment and placebo 
arms in terms of the cure rate or manifestations of acute 
bronchitis (fever, cough and purulent expectoration), 
the outcome of which was similar in the two groups. 
However, the regimen used in this trial had a preventive 
effect on secondary sites of infection (approaching 
statistical significance at the 5% level) after the 8-day 
treatment period, and this result was confirmed at the 
follow-up assessment on day 28. We did not analyze 
risk factors for superinfections. As regards quality of 
life, the study indicated more favorable changes in 
subjective overall health after the 8-day treatment 
period in the treatment group; also, the difference 
between the scores for overall subjective health between 
DO and D8 was positive in the treatment group and 
negative in the placebo group. 
Several studies have shown that community practi- 
tioners prescribe antibiotics to most patients with acute 
bronchitis [24,25]. A recent study of prescribing habits 
in France [25) showed that 82.2% of patients with 
acute lower respiratory tract infection examined by 
general practitioners were given antibiotics. According 
to Gonzalez and Sande [24], and as underlined in 
consensus conferences [ 1,6], antibiotics are routinely 
overprescribed to otherwise healthy adults with acute 
bronchitis. However, pathophysiologic data and clinical 
experience support the use of antibiotics for patients 
with risk factors such as age (patients aged 55 years and 
over) [2] and smoking [12]. Our study demonstrates 
that antibiotic therapy of acute bronchitis in otherwise 
healthy subjects under 65 years of age may give some 
benefits in the risk of secondary focal infections and 
quality of life. Further studies are required to confirm 
our findings. 
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